ALSO NOTED: ViaCell in new deal; Poniard gets fast track; CV releases data; and much more...

> Shares of ViaCell took off yesterday after the company inked a deal with EMD Serono for support on the development of ViaCyte, an experimental product for the cryopreservation and thawing of human oocytes. Report

> Poniard Pharmaceuticals has been fast tracked by the FDA for its lead product candidate, picoplatin, for the second-line treatment of refractory or resistant small cell lung cancer. Release

> CV Therapeutics announced today that data published in Circulation and presented at the European Society of Cardiology Congress 2007 in Vienna, Austria shows that Ranexa reduced both ventricular and atrial arrhythmias in patients receiving Ranexa compared to placebo in the MERLIN TIMI-36 study. Release

And Finally…The number of children diagnosed as bipolar has exploded recently, raising the argument whether the powerful drugs that they are being prescribed for them are really warranted. Article

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.